NATURAL COMPLEX OF FERMENTABLE DIETARY FIBERS AND SHORT CHAIN FATTY ACIDS IN PROINFLAMMATORY STATUS CORRECTION

Abstract

Aim. To study the influence of a natural complex of short chain fatty acids (SCFA), as inhibitors of histondeacetylases and fermentable dietary fibers (FDF), as SCFA precursors on the immunogram indices in patients with inflammatory processes of different localization. Materials and methods. Twenty one patients received a natural complex of FDF and SCFA - BAS “Rekicen RD®” - 1 table-spoon or 1 dessert-spoon (depending on age) 3 timed a day, 30 minutes prior to food intake. The generally accepted methods were used to study different parameters of immune status before and after taking a natural FDF and SCFA complex. Results. The normalizing influence of a natural FDF and SCFA complex on the total number of lymphocytes, monocytes, intensity of phagocytosis, IgA, IgM, IL-1β concentration as well as the number palpable lymph nodes was established in patients. Conclusions. The analyzed data indicated that the FDF and SCFA complex used, statistically significantly reduces proinflammatory cytokine IL-1ß level to the norm, thus contributing to normalization of immunogram parameters.

Keywords

Inflammation / immunogram / short chain fatty acids / histondeacetylase inhibitors

References

[1] Косарева П.В., Кузнецов В.Ф., Аверья-нова Н.И. Условно-патогенная флора кишечника как источник эндогенного инфицирования при пиелонефрите. Казанский медицинский журнал 2009; 90 (1): 110-111.

[2] Кузнецов В.Ф., Давидов М.И., Обернебесова Т.П. Фагоцитарный тест в оценке антимикробной защиты при воспалительных урологических заболеваниях Урология и нефрология 1995; 1: 16-18.

[3] Кузнецов В.Ф., Кулемин Л.М., Бондаренко В.М. Ферментированные пищевые волокна и короткоцепочечные жирные кислоты как компонент функционального питания. Вятский медицинский вестник. Материалы Всероссийской научно-практической конференции «Актуальные вопросы современной биохимии», посвященной 20-летию Кировской государственной медицинской академии 2007; 4: 188-192.

[4] Кузнецов С.В., Кузнецов В.Ф., Хоринко В.П., Кулемин Л.М. Возрастные особенности соотношения регенерации и повреждения гепатоцитов крыс при стрессе и патогенетические аспекты их коррекции. Пермский медицинский журнал 2012; 29 (3): 84-92.

[5] Baeuerle P.A., Henkel T. Function and activation of NFkappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.

[6] Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.

[7] Canani R.B., Di Costanzo M., Leone L., Pedata M., Meli R., Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17 (12): 1519-1528.

[8] Diakos C., Prieschl E.E., Säemann M.D., Böhmig G.A., Csonga R., Sobanov Y., Baumruker T., Zlabinger G.J. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. Biochem Biophys Res Commun 2006; 20. 349(2): 863-868.

[9] Hursting S.D., Dunlap S.M., Ford N.A., Hursting M.J., Lashinger L.M. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer & Metabolism 2013; 1: 10.

[10] Inan M.S., Rasoulpour R.J., Yin L., Hubbard A.K., Rosenberg D.W., Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118: 724-734.

[11] Jobin C., Sartor R.B. The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am J Physiol Cell Physiol 2000; 278: 451-462.

[12] McTiernan C.F., Lemster B.H., Frye C., Brooks S., Combes A., Feldman A.M. Interleukin-1β inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res 1997; 81 (4): 493-503.

[13] Meijer K., de Vos P., Priebe M.G. Butyrate and other shortchain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care 2010; 13: 715-721.

[14] Rezaie A., Parker R.D., Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021.

[15] Segain J.P., Raingeard de la Bletiere D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottiere H.M., Galmiche J.P. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 2000; 47: 397-403.

[16] Schwab M., Reynders V., Loitsch S., Steinhilber D., Stein J., Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 2007; 44: 3625-3632.

[17] Sina C., Gavrilova O., Forster M., Till A., Derer S., Hildebrand F., Raabe B., Chalaris A., Scheller J., Rehmann A., Franke A., Ott S., Hasler R., Nikolaus S., Folsch U.R., Rose-John S., Jiang H.P., Li J., Schreiber S., Rosenstiel P. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 2009; 183: 7514-7522.

[18] Skrzydlewska E., Sulkowski S., Koda M., Zalewski B., Kanczuga Koda L., Sulkowska M. Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol 2005; 11: 403-406.

[19] Thibault R., Blachier F., Darcy-Vrillon B., de Coppet P., Bourreille A., Segain J.P. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 2010; 16: 684-695.

[20] Yazısız V. Similarities and differences between Behcet's disease and Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(3): 228-238.

RIGHTS & PERMISSIONS

Kuznetsov S.V., Kuznetsov V.F., Negodyaeva N.L., Obernebesova T.P.